Osteoporosis Treatment by a New Active Vitamin D3 Compound, Eldecalcitol, in Japan
Osteoporosis Treatment by a New Active Vitamin D3 Compound, Eldecalcitol, in Japan
复制标题
日本采用新型活性维生素 D3 化合物 Eldecalcitol 治疗骨质疏松症
DOI：
10.1007/s11914-012-0116-1
复制
发表时间：
2012
影响因子：
4.3
通讯作者：
Toshio Matsumoto
中科院分区：
文献类型：
--
作者：
Toshio Matsumoto
虽然维生素D主要用作骨质疏松症治疗中的营养补充剂，但其活性形式1，25-二羟基维生素D [1，25（OH）2D]也具有维持骨重建平衡的作用。艾地骨化醇是1，25（OH）2D 3的类似物，在改善骨质疏松患者的骨重建平衡和增加骨密度方面比其天然形式具有更强的作用。每日0.75 μg艾地骨化醇在预防维生素D补充下新发椎骨骨折方面上级1.0 μg阿法骨化醇，在日本被批准用于骨质疏松症治疗。艾地骨化醇也能减少腕部骨折。需要进一步研究艾地骨化醇对其他非椎骨骨折、包括福尔斯在内的骨折外系统的影响，以及与其他药物联合治疗骨质疏松患者，以及艾地骨化醇的作用机制。
Although vitamin D is used mainly as a nutritional supplement in osteoporosis treatment, its active form, 1,25-dihydroxyvitamin D [1,25(OH)2D], has an effect to maintain bone remodeling balance as well. Eldecalcitol is an analog of 1,25(OH) 2D3 with stronger effects than its native form in improving bone remodeling balance and increasing bone mineral density in osteoporotic patients. Daily 0.75 μg eldecalcitol is superior to 1.0 μg alfacalcidol in preventing new vertebral fractures under vitamin D supplementation, and is approved for osteoporosis treatment in Japan. Eldecalcitol also decreases wrist fractures. Further studies are warranted to examine the effect of eldecalcitol on other nonvertebral fractures, extraskeletal systems including falls, and combined treatment with other drugs in osteoporotic patients, as well as the mechanism of action of eldecalcitol.
影响因子：
5.8
作者：
Matsumoto, T;Miki, T;Nakamura, T
通讯作者：
Nakamura, T
DOI：
10.1016/j.jsbmb.2006.12.025
发表时间：
2007-03
期刊：
The Journal of Steroid Biochemistry and Molecular Biology
影响因子：
--
作者：
S. Hatakeyama;S. Nagashima;N. Imai;Keisuke Takahashi;Jun Ishihara;A. Sugita;T. Nihei;H. Saito;F. Takahashi;N. Kubodera
通讯作者：
S. Hatakeyama;S. Nagashima;N. Imai;Keisuke Takahashi;Jun Ishihara;A. Sugita;T. Nihei;H. Saito;F. Takahashi;N. Kubodera